Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from enGene Holdings (ENGN).
enGene Holdings Inc. has refreshed its Corporate Presentation, highlighting its promising lead program, detalimogene voraplasmid, a non-viral genetic medicine for Non-Muscle Invasive Bladder Cancer (NMIBC). The company outlines the potential of this treatment in a market projected to exceed $20 billion, emphasizing its unique blend of efficacy, safety, and user-friendliness, with an estimated BLA filing by mid-2026. Investors should note that forward-looking statements are based on current management expectations and are subject to risks and uncertainties.
See more data about ENGN stock on TipRanks’ Stock Analysis page.